SCHEMBL6467474

SCHEMBL6467474

CCCCOc1cccc(N)c1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
ALDH1A1 P00352 2/20 0.48
HSD17B10 Q99714 2/20 0.48
PPARA Q07869 2/20 0.47
MEN1 O00255 1/20 0.47
NR1I2 O75469 1/20 0.47
LMNA P02545 1/20 0.47
CHRM2 P08172 1/20 0.47
CYP3A4 P08684 1/20 0.47
ADRA2A P08913 1/20 0.47
MAPT P10636 1/20 0.47
OPRK1 P41145 1/20 0.47
HTR2B P41595 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
TP53 P04637 2/20 0.46
TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10795237 0.92 CYP1A2 (0.49) CYP1A2CYP2C9CYP2C19ALDH1A1PPARA
SCHEMBL28423316 0.89 CA12 (0.55) CYP1A2CYP2C9CYP2C19PPARAMEN1
SCHEMBL11445471 0.88 CYP1A2 (0.60) CYP1A2CYP2C9CYP2C19ALDH1A1HSD17B10
SCHEMBL6469761 0.85 ALDH1A1 (0.56) ALDH1A1HSD17B10LMNAMAPTTSHR
SCHEMBL4960097 0.83 PTPN1 (0.60) ALDH1A1PPARAMEN1MAPTKMT2A
SCHEMBL10339837 0.83 TP53 (0.50) CYP1A2CYP2C9CYP2C19PPARATP53
SCHEMBL6840729 0.83 KMT2A (0.51) ALDH1A1PPARAMEN1NR1I2LMNA
SCHEMBL29109655 0.83 PPARA (0.58) CYP1A2CYP2C9CYP2C19PPARAMAPT
SCHEMBL1558023 0.82 KDM4E (0.52) ALDH1A1LMNAPTPN1CA12CA1
SCHEMBL24136176 0.81 PTPN1 (0.59) PPARATP53TSHRPTPN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed
US-4154745-A Isobenzofuran route to anthracycloquinones RESEARCH CORPORATION (US) 1979-05-15 US disclosed
US-4116981-A 5,12-EPOXY-NAPHTHACENE-6,11-DIONE DERIVATIVES Tsay, Yuh-Geng (TW) 1978-09-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB CYP1A2 1224/4885CYP2C9 1617/4885CYP2C19 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.